Volcano Announces New iPad Teaching Application for Its Recently-Released Visions® PV .035 Digital IVUS Catheter

  Volcano Announces New iPad Teaching Application for Its Recently-Released
                    Visions® PV .035 Digital IVUS Catheter

Interactive Educational Tool Simulates IVUS-Guided Treatment of Aortic
Aneurysms

PR Newswire

SAN DIEGO, Feb. 1, 2013

SAN DIEGO, Feb. 1, 2013 /PRNewswire/ --Volcano Corporation (Nasdaq: VOLC) a
leading developer and manufacturer of precision guided therapy tools designed
to enhance the diagnosis and treatment of coronary and peripheral vascular
disease, today announced it has a new interactive educational tool to
facilitate learning about IVUS-guided interventional procedures with its new
Visions^® PV .035 Digital IVUS Catheter. The new Aortic IVUS App for iPad,
available on the Apple App Store, provides case examples with interactive
education on the procedural workflow and image interpretation, and is intended
for healthcare professionals involved in endovascular aortic procedures.

"I am glad Volcano saw the utility of developing an app for IVUS technique and
image interpretation," said Jacques Kpodonu, MD, Cardiovascular Surgeon and
Surgical Director of the Cardiac Hybrid and Endovascular Therapies Program at
Hoag Memorial Presbyterian Hospital, Newport Beach, CA. Dr. Kpodonu, who
assisted in the app's development, explained, "A multimedia-based, animated
demonstration of IVUS video co-registered with the catheter's position in the
aorta is an ideal way to explain the endoaortic surgical procedural steps
along with the images. This tool could be very helpful for fellows and
physicians wanting to learn about a low contrast IVUS-guided surgical approach
to endovascular aortic repair (EVAR) and thoracic endovascular aortic repair
(TEVAR)."

Volcano chose its new Visions PV.035 Digital IVUS Catheter for the educational
tool because it offers an opportunity for an interventional solution using
less contrast which may be beneficial for renal insufficient patients.
According to company officials, IVUS may be used in some cases instead of an
initial contrast angiogram to identify anatomical landmarks during
endovascular aortic repair. Furthermore, the Visions PV .035 catheter
incorporates new centimeter markers that enable the user to make length
measurements between landmarks without the need for other devices.

Frank Arko, MD, Director of Endovascular Surgery at the Sanger Heart and
Vascular Institute, Carolinas Medical Center, Charlotte, NC said, "With the
new catheter, I can more easily accomplish a case with very little contrast."

Company executives highlighted other catheter enhancements compared to the
existing Visions PV 8.2 catheter, including a longer connector length to
improve procedural flexibility, new materials allowing for a softer, more
rounded tip with lower entry profile and GlyDx® hydrophilic coating to aid in
delivery through tortuous anatomy. The catheter is now available for all
customers in the US and Europe (CE countries).

About Volcano Corporation
Volcano Corporation is revolutionizing the medical device industry with a
broad suite of technologies that make imaging and therapy simpler, more
informative and less invasive. Its products empower physicians around the
world with a new generation of analytical tools that deliver more meaningful
information - using sound and light as the guiding elements. Founded in
cardiovascular care and expanding into other specialties, Volcano is changing
the assumption about what is possible in improving patient outcomes by
combining imaging and therapy together.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995. Any statements in
this release that are not historical facts may be considered "forward-looking
statements" including statements regarding the potential benefits of the the
iPad application, PV.035, and other products, procedures and technologies
described above, the pace and extent of market adoption of the company's
PV.035 product and other technologies, and the impact of clinical and other
technical data. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may cause
Volcano's results to differ materially and adversely from the statements
contained herein. Some of the potential risks and uncertainties that could
cause actual results to differ include the pace and extent of market adoption
of the company's products and technologies; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; unexpected regulatory actions or delays or government
regulation generally; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection; competition in general;
government, industry and general public pricing pressures; unexpected
manufacturing issues; growth strategies; timing and achievement of product
development milestones; outcome of ongoing litigation; the impact and benefits
of market development; product introductions; unexpected new data, safety and
technical issues; market conditions; and other risks inherent to medical
device development and commercialization. These and additional risks and
uncertainties are more fully described in Volcano's filings made with the
Securities and Exchange Commission, including our recent Form 424(b)(2)
prospectus supplement. Undue reliance should not be placed on forward-looking
statements which speak only as of the date they are made. Volcano undertakes
no obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made, or to
reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation

Website: http://www.volcanocorp.com
Contact: Media, Edrienne Brandon, +1-858-720-4136, ebrandon@volcanocorp.com,
Investor, Neal Rosen, +1-650-458-3014, nrosen@volcanocorp.com